Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing its financial and operating results for the fourth quarter and full year ended December 31, 2024. The report also announces significant capital allocation decisions by the company's board of directors, marking a new phase in returning value to shareholders. Investors should note the initiation of a quarterly cash dividend program and a substantial share repurchase authorization alongside the earnings release. The company declared its inaugural quarterly cash dividend of $0.88 per share, payable on March 20, 2025, to shareholders of record on February 20, 2025. This signifies a commitment to consistent shareholder returns. Furthermore, Regeneron has authorized an additional $3.0 billion for share repurchases, underscoring confidence in its financial position and the company's valuation. The full details of the financial and operating results are available in the accompanying press release (Exhibit 99.1).
Key Highlights
- 1Regeneron announced its financial and operating results for Q4 and Full Year 2024 on February 4, 2025.
- 2The company's board of directors has initiated a quarterly cash dividend program.
- 3An initial cash dividend of $0.88 per share has been declared.
- 4The dividend will be paid on March 20, 2025, to shareholders of record as of February 20, 2025.
- 5Regeneron authorized an additional $3.0 billion share repurchase program.
- 6The press release containing the Q4 and Full Year 2024 financial and operating results is filed as Exhibit 99.1.